http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007112098-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1dd98ad4ee076841fec541542f952f58
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33
filingDate 2007-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e69df28542b7d5568db0f03c1a2b0bad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_641aad445ef683dfb43a01e93211a415
publicationDate 2008-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2007112098-A3
titleOfInvention Uses of diphenyl/diphenylamine carboxylic acids
abstract The present invention demonstrates that chemical-induced degradation of Sp proteins by a specific sub-class of NSAIDs inhibited cancer cell growth, angiogenesis and metastasis of cancer cells. The inhibitory effects of these compounds were demonstrated in vitro and in vivo. Hence, the results discussed herein indicate that these compounds can be used to inhibit cell growth, angiogenesis and metastasis in cancers such as pancreatic, breast, prostate, colon, bladder and ovarian cancers.
priorityDate 2006-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004102434-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2001034361-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004220155-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393346
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11487

Total number of triples: 21.